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The Unstoppable Attraction for
Induced Pluripotent Stem Cells
Are They the Magic Bullet for Modeling
Inherited Arrhythmogenic Diseases?*
Massimiliano Gnecchi, MD, PHD,†‡
Peter J. Schwartz, MD†‡§¶
Pavia, Italy; Cape Town and Tygerberg, South Africa;
and Riyadh, Saudi Arabia
In this issue of the Journal, the group led by Lior Gepstein
(1) presents data on the electrophysiological properties of
cardiomyocytes (CMs) derived from induced pluripotent
stem cells (iPSCs) of patients affected by catecholaminergic
polymorphic ventricular tachycardia (CPVT). The study
adds important information on how iPSCs can be used for
modeling inherited arrhythmogenic disorders and, perhaps,
for developing personalized therapies for these life-
threatening diseases. Here, we will briefly review the amaz-
ingly rapid development of iPSC technology and this new
important contribution.
See page 990
A step forward in cardiovascular research: iPSC-derived
CMs. Year 2006 will be remembered in science for the first
report describing the generation of iPSCs from mouse
somatic cells (2). Ever since, research on iPSCs has ex-
ploded. Rapidly, human iPSCs have been generated either
by transducing fibroblasts with a combination of retroviruses
encoding the original 4 transcription factors (Oct3/4, Sox2,
Klf4, and c-Myc) or by an independently determined
combination of lentivirally transduced genes (Oct4, Sox2,
NANOG, and Lin28) (3,4). These human iPSCs are
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and gene expression, and they can differentiate into cell
types of the 3 germ layers in vitro and in vivo. Like
embryonic stem cells, iPSCs can be used for studies of basic
developmental biology. Most importantly, it is possible to
generate from iPSCs theoretically unlimited amounts of
terminally differentiated cells that can be used for regener-
ative therapies but also for drug screening or disease
modeling (Fig. 1).
Several investigators have now described methods to
differentiate iPSCs into functional CMs (iPSC-CMs) (Fig.
1) (5). iPSC-CMs express a large number of cardiac-specific
markers, and structural proteins form well-organized sarco-
meres. Both mouse and human iPSC-CMs can generate
typical nodal/pacemaker-, atrial-, and ventricular-like action
potentials, display physiological adaptation in action poten-
tial duration to changes in heart rate, and respond to
adrenergic stimulation (6). Importantly, iPSC-CMs express
ion channels and regulators of intracellular calcium (Ca2)
physiology (7).
Based on this bulk of scientific evidence, it was rather
straightforward to hypothesize that by using this technique,
it would have been possible to unravel disease mechanisms
underlying the clinical manifestations of several cardiac
disorders. Among them, inherited arrhythmogenic disor-
ders certainly represent the ideal model, and it comes as no
surprise that they have been the object of very active
research.
Patient-specific iPSC-CMs and arrhythmogenic diseases.
Patient-specific iPSC-CMs have been characterized for
long-QT syndrome (LQTS) types 1, 2 and 3 (8–10), for
Timothy syndrome (11), and now also for CPVT (1,12,13).
The first report describing LQTS type 1 patient-specific
iPSC-CMs demonstrated that the cells were able to reca-
pitulate the electrophysiological properties of the disorder:
they exhibited prolongation of action potential duration,
altered Iks activation and deactivation properties, and ab-
ormal response to catecholamine stimulation that was
revented by beta-blockers (8). iPSC-CMs derived from
atients affected by LQTS type 2 displayed significant
rolongation of the action potential duration due to signif-
cant reduction of the Ikr current (9). Most importantly,
hese iPSC-CMs revealed marked arrhythmogenicity char-
cterized by early afterdepolarizations and triggered activity.
n addition, LQTS type 3 can be modeled using iPSCs (10).
ibroblasts from knock-in mouse with an in-frame deletion
n the SCN5A gene were reprogrammed into iPSCs and
hen differentiated into iPSC-CMs that showed delayed
nactivation of INa and prolonged action potential duration.
otably, the action potential duration could be shortened in
esponse to rapid pacing, a behavior now accepted as typical
f LQTS type 3 patients and which we had postulated in
995 (14) a few months after the identification of SCN5A as
he disease-gene for LQTS type 3 (15).
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involves another important channelopathy, CPVT. For this
disease it is important to remember that coordinated release
of Ca2 from the sarcoplasmic reticulum (SR) through
cardiac ryanodine receptor isoform 2 (RyR2) channels is
essential for CMs function. In CPVT, an inherited disease
characterized by stress-induced ventricular arrhythmias in
young patients with structurally normal hearts (16), auto-
somal dominant mutations in RyR2 or recessive mutations
in calsequestrin lead to aberrant diastolic Ca2 release from
the SR causing arrhythmogenic delayed afterdepolarizations
(DADs). Itzaki et al. (1) report the generation of iPSC-
CMs from a CPVT patient carrying a M4109R heterozy-
gous point RyR2 mutation. In patient-specific iPSC-CMs,
intracellular electrophysiological recording demonstrated
the occurrence of DADs in almost 70% of the cells studied
compared with a limited 10% in control CMs. Stimulation
of iPSC-CMs with isoproterenol or forskolin increased
both the frequency and the magnitude of DADs and
simulated triggered activity. Catecholaminergic stress led to
significant whole-cell [Ca2] transient irregularities that
improved with the use of beta-blockers. This elegant study
by Itzaki et al. represents a promising step forward analyzing
in detail the mechanisms involved in the pathophysiology of
CPVT and testing the most appropriate therapy according
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Figure 1 Possible Applications of Patient-Specific iPSC-CMs
Different types of somatic cells can be reprogrammed to the pluripotent state (iPS
diomyocytes (iPSC-CMs) or other differentiated cell types. The possible application
drug discovery and cardiotoxicity, and for disease modeling. Inherited arrhythmoge
CMs. CPVT  catecholaminergic polymorphic ventricular tachycardia; 2D  2-dime
induced pluripotent stem cells; LQTS  long-QT syndrome.to the disease-causing mutation.However, the current study is not the very first describing
iPSC-CMs from CPVT patients. Indeed, during the review
process of the paper by Itzaki et al. (1), 2 other groups have
independently generated, characterized, and reported works
on iPSC-CMs derived from CPVT patients (12,13). This
coincidence testifies once more to the frenetic activity in the
iPSCs field but does not minimize the importance of the
work of Itzaki et al. that fully agrees with what has been
shown by the other investigators. Jung et al. (13) reported
the generation of iPSCs-CMs from a patient carrying a
novel RyR2 S406L mutation. Catecholaminergic stress led
to elevated diastolic [Ca2], a reduced SR Ca2 content,
nd an increased susceptibility to DADs and arrhythmia
ompared with control CMs. These findings were due to
ncreased frequency and duration of elementary Ca2 re-
lease events (Ca2 sparks). Importantly, the authors were
able to show that dantrolene, a drug effective against
malignant hyperthermia, restored normal Ca2 sparks and
rescued the arrhythmogenic phenotype. The study from
Ofer Binah’s group. (12) focused on the form of CPVT
caused by the missense mutation D307H in the cardiac
calsequestrin gene, CASQ2. The authors demonstrated that
iPSCs generated from skin fibroblasts of 2 patients affected
by the disease carry the CASQ2 mutation. Next, they
generated iPSC-CMs expressing the mutant CASQ2 pro-
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and diastolic [Ca2](i) rise. Interestingly, electron micros-
copy analysis revealed that, compared with control cells,
CPVT iPSC-CMs had a more immature phenotype with
less organized myofibrils, enlarged sarcoplasmic reticu-
lum cisternae, and reduced number of caveolae. To-
gether, these 3 studies strongly support the breakthrough
concept that patient-specific iPSC-CMs can be used to
study the electrophysiological mechanisms underlying
CPVT.
Future directions and limitations. The generation of
disease-specific iPSC-CMs represents an important step
forward in cardiovascular research in general, and in the
field of cardiac arrhythmias in particular, because human
CMs cannot be routinely isolated from patients. Because of
this limitation, up to now heterologous expression in non-
cardiomyocytes has been used for single-cell electrophysio-
logical and ion channel studies. However, these modified
cells fail to reproduce the complex system of CMs. Further-
more, mouse models are questionable: in mice, the ion
channels that contribute to the cardiac action potential are
remarkably different from those of humans. Thus, there is
great expectation that iPSC-CMs will allow the unraveling
of unsuspected mechanisms underlying the clinical manifes-
tations of inherited arrhythmias. For example, despite re-
cent advances in the comprehension of the genetic basis of
LQTS, in 25% of patients with a clear phenotype a genetic
defect is not yet identified; this has a negative impact on the
clinical management of these patients and of their families
because it prevents the very important “cascade” screening
(17). It can be hypothesized that, by using the iPSC-CMs
technology, it will soon be possible to discover typical
electrophysiological features that may shed light into the
specific disease mechanism and eventually drive a targeted
therapeutic strategy. The iPSC-CMs might also be used to
clarify the role of modifier genes (18,19).
Despite all the excitement around iPSCs, there are still
several issues that must be solved before this promising
technology can be used for clinical purposes. For example,
the reprogramming efficiency of somatic cells into iPSCs is
still low. Use of small molecules has been proposed to
improve the reprogramming efficiency or completely replace
1 or more reprogramming factors (5). The same approach
may also be used to improve the differentiation of iPSCs
into CMs and to push the differentiation to the stage of fully
mature CMs since today we are not quite there. Of
relevance, current differentiation strategies lead to the gen-
eration of a mix population of nodal/pacemaker-, atrial-,
and ventricular-like cells: although the mixed cell popula-
tion is adequate for some studies, almost pure CMs are
needed for other uses. The most promising methods to
enable CMs identification and isolation are the transgenic
selections, that yield a purity of 90%; it remains to be
established if this further genetic modification may affect
the characteristics of the iPSC-CMs. Recently, it has been
proposed that epitopes such as EMLIN, SIRPA, andVCAM can be used to successfully sort a fairly homoge-
neous population of CMs (20). Dermal fibroblasts are the
cell type most widely used for reprogramming. However,
this method requires a skin biopsy, which candidates some-
times refuse. The search for other cell types requiring less
invasive procedures for their collection led to the description
of circulating CD34 cells and keratinocytes as suitable
ources for cell reprogramming (20). Also, urinary renal
ubular epithelial cells, isolated from patient’s urine, have
een successfully reprogrammed to iPSCs with high effi-
iency; the totally noninvasive method to collect them
ertainly represents a great advantage (21). Lastly, it is
orth noting the urgent need for standardization of the
arameters that define iPSCs in general, and iPSC-CMs in
articular, to facilitate the comparison between the results
btained by different groups.
Despite the existence of undeniable problems still requir-
ng solution, it has to be said that the enthusiasm present in
any laboratories for the potential implications of iPSC-
Ms methods is understandable. Wearing the 2 hats of
aboratory and clinical work, we cannot help being cau-
iously intrigued by this new step toward translational
esearch and totally open-minded about its potential clinical
mplications.
Acknowledgment
The authors thank Elisabetta Cervio for her editorial
support.
Reprint requests and correspondence: Dr. Peter J. Schwartz,
Department of Molecular Medicine, University of Pavia, c/o
Fondazione IRCCS Policlinico S. Matteo, V.le Golgi, 19, 27100
Pavia, Italy. E-mail: peter.schwartz@unipv.it.
REFERENCES
1. Itzhaki I, Maizels L, Huber I, et al. Modeling of catecholaminergic
polymorphic ventricular tachycardia with patient-specific human-
induced pluripotent stem cells. J Am Coll Cardiol 2012;60:990–1000.
2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors. Cell
2006;126:663–76.
3. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent
stem cells from adult human fibroblasts by defined factors. Cell
2007;131:861–72.
4. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent
stem cell lines derived from human somatic cells. Science 2007;
318:1917–20.
5. Narsinh K, Narsinh KH, Wu JC. Derivation of human induced
pluripotent stem cells for cardiovascular disease modeling. Circ Res
2011;108:1146–56.
6. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes
derived from human induced pluripotent stem cells. Circ Res 2009;
104:e30–41.
7. Satin J, Itzhaki I, Rapoport S, et al. Calcium handling in human
embryonic stem cell-derived cardiomyocytes. Stem Cells 2008;26:
1961–72.
8. Moretti A, Bellin M, Welling A, et al. Patient-specific induced
pluripotent stem-cell models for long-QT syndrome. N Engl J Med
2010;363:1397–409.
9. Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome
with induced pluripotent stem cells. Nature 2011;471:225–9.
1004 Gnecchi and Schwartz JACC Vol. 60, No. 11, 2012
iPSCs and Catecholaminergic Polymorphic Ventricular Tachycardia September 11, 2012:1001–410. Malan D, Friedrichs S, Fleischmann BK, Sasse P. Cardiomyocytes
obtained from induced pluripotent stem cells with long-QT syndrome
3 recapitulate typical disease-specific features in vitro. Circ Res
2011;109:841–7.
11. Yazawa M, Hsueh B, Jia X, et al. Using induced pluripotent stem cells
to investigate cardiac phenotypes in Timothy syndrome. Nature
2011;471:230–4.
12. Novak A, Barad L, Zeevi-Levin N, et al. Cardiomyocytes generated
from CPVT(D307H) patients are arrhythmogenic in response to
beta-adrenergic stimulation. J Cell Mol Med 2012;16:468–82.
13. Jung CB, Moretti A, Mederos y Schnitzler M, et al. Dantrolene
rescues arrhythmogenic RYR2 defect in a patient-specific stem cell
model of catecholaminergic polymorphic ventricular tachycardia.
EMBO Mol Med 2012;4:180–91.
14. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients
with mutations of the SCN5A and HERG genes have differential
responses to Na channel blockade and to increases in heart rate.
Implications for gene-specific therapy. Circulation 1995;92:3381–6.15. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an
inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80:805–11.16. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors
of arrhythmic events in catecholaminergic polymorphic ventricular
tachycardia. Circulation 2009;119:2426–34.
17. Schwartz PJ. Cascades or waterfalls, the cataracts of genetic screening
are being opened on clinical cardiology. J Am Coll Cardiol 2010;55:
2577–9.
18. Crotti L, Monti MC, Insolia R, et al. NOS1AP is a genetic modifier
of the long-QT syndrome. Circulation 2009;120:1657–63.
19. Schwartz PJ, Crotti L, Insolia R. Long QT syndrome: From genetics
to management. Circ Arrhythm Electrophysiol 2012;5:868–77.
20. Burridge PW, Keller G, Gold JD, Wu JC. Production of de novo
cardiomyocytes: Human pluripotent stem cell differentiation and direct
reprogramming. Cell Stem Cell 2012;10:16–28.
21. Zhou T, Benda C, Duzinger S, et al. Generation of induced pluripo-
tent stem cells from urine. J Am Soc Nephrol 2011;22:1221–8.
Key Words: cardiomyocytes y catecholaminergic polymorphic
ventricular tachycardia y human-induced pluripotent stem cells y
inherited arrhythmogenic diseases y long QT syndrome.
